Sharabi K, Lin H, Tavares CDJ, et al. Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell. 2017;169(1):148-160.e15. doi:10.1016/j.cell.2017.03.001.

Emdin CA, Klarin D, Natarajan P, et al. Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes. 2017;66(8):2310-2315. doi:10.2337/db17-0149.

Latva-Rasku A, Honka M-J, Stančáková A, et al. A Partial Loss-of-Function Variant in Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study. Diabetes. 2018;67(2):334-342. doi:10.2337/db17-1142.

Merino J, Florez JC. Precision medicine in diabetes: an opportunity for clinical translation. Ann N Y Acad Sci. 2018;1411(1):140-152. doi:10.1111/nyas.13588.

Agostini M, Schoenmakers E, Beig J, et al. A Pharmacogenetic Approach to the Treatment of Patients With Mutations. Diabetes. 2018;67(6):1086-1092. doi:10.2337/db17-1236.

Chou DH-C, Bodycombe NE, Carrinski HA, et al. Small-Molecule Suppressors of Cytokine-Induced beta-Cell Apoptosis. ACS Chem Biol. 2010;5(8):729-34. doi:10.1021/cb100129d.

Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508(7494):108-12. doi:10.1038/nature13110.

Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63(8):2590-9. doi:10.2337/db13-1367.

Segrè AV, Wei N, DIAGRAM consortium, MAGIC Investigators, Altshuler D, Florez JC. Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk. Diabetes. 2015;64(4):1470-83. doi:10.2337/db14-0703.

Walford GA, Davis J, Warner S, et al. Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism. 2013;62(12):1772-8. doi:10.1016/j.metabol.2013.07.003.